Skip to main content
. 2016 Feb 10;127(17):2131–2143. doi: 10.1182/blood-2015-11-681171

Figure 2.

Figure 2

ABL1 inhibits expansion of BCR-ABL1–positive LSCs. (A) Mean percentage ± SD of GFP+Lin−c-Kit+Sca-1+ LSCs in freshly established (0 weeks) and 5-week-old (5 weeks) BCR-ABL1 Abl1−/− and BCR-ABL1 Abl1+/+ cells. (B) Mean percentage ± SD of quiescent LSCs (CPDmax Lin−c-Kit+Sca-1+), LT-LSCs (Lin−c-Kit+Sca-1+CD34−Flt3−), and ST-LSCs (Lin−c-Kit+Sca-1+CD34+Flt3−) in BCR-ABL1 Abl1−/− and BCR-ABL1 Abl1+/+ leukemia cell populations. (C) Bars represent mean percentage ± SD of GFP+Lin−c-Kit+Sca-1+ LSCs in BMCs isolated from moribund SCID mice transplanted with freshly established (0 weeks) and 5-week-old cultured (5 weeks) BCR-ABL1 Abl1−/− and BCR-ABL1 Abl1+/+ cells (see Figure 1). **P < .05, *P < .001 as determined by the unpaired Student t test; ns = not significant. (D) Statistically significant (false discovery rate [FDR] < 0.05) fold changes (>1.5) of expression of indicated genes regulating “stemness” in BCR-ABL1 Abl1−/− vs BCR-ABL1 Abl1+/+ leukemia cells maintained with SCF + IL-3.